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Summary
After radiosurgery of malignant tumors, it can be difficult to discriminate between transient treatment effects,
radiation necrosis, and tumor progression on post-treatment imaging. Misinterpretation of an enlarging lesion may
lead to inappropriate treatment and contribute to disagreements about treatment efficacy. In an effort to clarify
this problem, we reviewed our experience with interpreting post-radiosurgical imaging in patients with malignant
primary and secondary brain tumors. We reviewed results of radiosurgery of 30 malignant gliomas and 35 metastatic
brain tumors with minimum follow up of 1 year or until death. Of 30 gliomas, 73% were larger a mean of 13 weeks
after radiosurgery. Of 35 metatstatic tumors, 22% were larger a mean of 10 weeks after radiosurgery. Eleven had
18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) of enlarging lesions. Eight showed increased
activity with respect to brain; three decreased activity. Of the eight, six predicted incorrectly based upon the patients’
subsequent courses (all alive, mean follow up of 27 months), and two correctly, with the patients dying from
the imaged lesions 8 and 13 months later. Of the three with FDG uptake less than brain, one patient was alive
with 32 weeks of follow up, and two patients died from the imaged lesion 13 and 21 months later. Radiographic
enlargement after radiosurgery is common, especially for gliomas. Physicians caring for these patients should be
aware of this phenomenon and be cautious in interpreting post-treatment images. MRI appearance may be useful for
metastases. FDG-PET seems unreliable. Further evaluation of Tl-201 and HMPAO SPECT or MRS is warranted.
Introduction
Stereotactic radiosurgery has become an accepted treat-
ment option for cerebral metastatic tumors [1–7] and
for recurrent gliomas [8–11]. After treatment, tumors
may regress or remain stable, but frequently, the
enhancing radiographic abnormality enlarges. Inter-
preting post-treatment images is difficult, and addi-
tional studies such as 18F-fluorodeoxyglucose-positron
emission tomography (FDG-PET) [7], thallium or
HMPAO SPECT [12–14], or biopsy [15] are often
used to try to discriminate between transient treat-
ment effects, radiation necrosis, and tumor progression.
Even when patients are doing well clinically, biopsy
may show persistent tumor at the radiosurgical site
[15]. There is not universal agreement on the value of
these studies and little literature on the management of
patients whose radiographic abnormality enlarges after
radiosurgery. Misinterpretation of an enlarging radio-
graphic abnormality may contribute to disagreements
about the efficacy of radiosurgery [16,17]. In an effort
to clarify this problem, we review our experience with
interpreting post-radiosurgical imaging in patients with
malignant primary and secondary brain tumors.
Methods
We reviewed our results for radiosurgical treatment
of all patients with malignant primary and secondary
brain tumors over a period of 5 years since the incep-
tion of our radiosurgery program in March, 1995.
Radiosurgery for gliomas was only offered in the set-
ting of recurrence after primary therapy. Determination
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of progression rather than radiation effect was made
at a multidisciplinary tumor board attended by radia-
tion oncologists, neuroradiologists, neuro-oncologists,
and neurosurgeons. MRI and FDG-PET scans and
occasional surgical biopsies were used to aid in
this determination. Radiosurgery for metastases was
offered for both primary treatment and for recur-
rences. Radiosurgical treatment was carried out using
the Brown–Roberts–Wells stereotactic head frame
(Radionics, Burlington, MA). All patients under-
went stereotactic, thin slice (1.0 or 1.5 mm), contrast
enhanced CT scans. Patients with very small tumors or
poor lesion definition on CT underwent image fusion
with MRI scans obtained prior to the day of treatment.
Data was transferred into the treatment planning system
(UMPLAN) [18,19] and the tumor was outlined on
each CT slice. Treatment planning and quality assur-
ance checking were carried out as previously described
[20]. Patients not previously on an anticonvulsant were
orally loaded with Dilantin. Patients already on an anti-
convulsant had their serum levels checked and addi-
tional medication was given if the level was not in
the high therapeutic range. All patients were given
Dexamethasone 10 mg orally prior to treatment.
Treatment was carried out on a Racetrack Microtron
accelerator (Scanditronix MM50) (Uppsalla, Sweden)
using a computer control system developed at the
University of Michigan [18]. The isocenter was first
localized with an orthogonal laser system and a com-
mercial laser target localization frame (Radionics,
Burlington, MA) and then confirmed with source to sur-
face distances and orthogonal radiographs which were
compared with digitally reconstructed radiographs
generated by the treatment planning system. Treatment
took approximately 30 min, after which patients were
discharged to home. Anticonvulsants were discontin-
ued unless the patient was on such medication prior to
treatment or had a history of seizures. Steroids doses
were adjusted according to clinical response and radio-
graphic data with an effort to use the lowest dose at
which the patients’ symptoms and side effects were
minimized. Patients underwent regular post-treatment
imaging, either by the referring oncologist or by the
Radiosurgery Program if they so desired.
Results
Over the last 5 years, 33 patients have been treated
for recurrent high grade glioma (10 glioblastomas,
9 grade III astrocytomas, 2 anaplastic ependymomas,
10 anaplastic oligoastrocytomas, and 2 malignant gan-
gliogliomas) and 58 metastatic tumors have been
treated in 52 patients. For the purposes of this study,
only patients with one year of follow up or who have
died were included. Imaging responses were grouped
into the following categories based upon subsequent
imaging:
1. Target lesion disappeared
2. Target lesion regressed
3. Target lesion stable
4. Target lesion larger
Thirty patients with gliomas had adequate follow up
(median 24 months). On imaging obtained a mean of
13 weeks after radiosurgery, 5 (17%) had regressed,
3 (10%) were stable, and 22 (73%) were larger. Of
the 22 patients whose lesions enlarged, seven under-
went reoperation, five received only steroids, seven
received chemotherapy, one received additional frac-
tionated radiation and chemotherapy, and two died
with no additional treatment. Pathology reports on the
operated patients showed recurrent high grade glioma
in four cases, pure radiation necrosis in two cases, and
mixed tumor and necrosis in one case.
Thirty-five patients with 37 metastatic tumors had
adequate follow up (median 25 months). On imag-
ing obtained a mean of 10 weeks after radiosurgery,
1 (2.9%) lesion had disappeared, 18 (49%) had
regressed, 10 (27%) were stable, and 8 (22%) were
larger. Of the eight lesions which enlarged, two were
treated with steroids only, three received chemother-
apy, one underwent reoperation, and two died with no
additional therapy. The pathology report on the one
reoperated patient showed mainly radiation necrosis,
but contained islands of adenocarcinoma cells. The
patient’s esophageal carcinoma subsequently recurred
in the scalp incision and he succumbed to his disease.
Eleven patients had FDG-PET scans as part of their
evaluation after enlarging lesions were detected. It was
our hypothesis that FDG uptake higher than that of
brain would indicate the presence of active tumor and
indicate that tumor progression was likely. Eight stud-
ies showed increased metabolic activity with respect
to normal brain, and three showed decreased activ-
ity. Of the eight studies read as increased activity, six
were thought to be incorrect based upon the patients’
subsequent courses (all alive with a mean follow up
of 27 months and without progression of the lesion
imaged), and two were correct with the patients dying
from the imaged lesions 8 and 13 months later. Of
the three studies showing decreased activity, one was
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correct with the patient alive but with only 8 weeks of
follow up, and two were incorrect with patients dying
from the imaged lesion 13 and 21 months later.
Five patients had 201thallium single photon emission
computed tomography (SPECT) as part of their evalu-
ation after enlarging lesions were detected. Three stud-
ies showed uptake of the tracer, and two showed no
uptake. Of three positive tests for tracer uptake, all three
patients died of the imaged lesion a mean of 9 months
later. Of two negative tests, one was correct with the
patient alive and well 20 months later, and one was
incorrect with the patient dying from the imaged lesion
13 months later.
Examples of imaging responses are given for
patients with persistent or enlarging lesions.
Target lesion regressed
T.W., a 50-year-old man, presented with headaches
and ataxia. CT revealed a right thalamic mass and
hydrocephalus. He underwent stereotactic biopsy
and ventriculoperitoneal shunting. Pathology revealed
non-small-cell lung cancer. He underwent fraction-
ated whole brain irradiation to 30 Gy and under-
went chemotherapy with carboplatin and Taxol. Six
months later, his symptoms recurred and CT and
MRI revealed a recurrence of his thalamic mass. He
was treated with radiosurgery, receiving 15 Gy to the
Figure 1. Metastatic large cell lung carcinoma. Gadolinium enhanced T1 weighted axial MRI from day of treatment (left), and contrasted
enhanced axial CT scans from 2 (center) and 5 (right) months after radiosurgery for a recurrent metastatic large cell lung cancer, treated
with 15 Gy to the 82% isodose surface of a 10.9 cc mass. The lesion has regressed in size and lost its central enhancement, but has not
disappeared.
82% isodose surface of a 10.9 cc target. Subsequent
imaging 5 months later showed marked diminution in
the size of the enhancing mass, but persisting perile-
sional edema. He continued to require steroids for the
remainder of his life, and succumbed to systemic dis-
ease 9 months after radiosurgery (Figure 1).
Target lesion stable
K.G., a 51-year-old woman, was diagnosed with non-
small-cell lung cancer and treated with chemother-
apy, radiation, and resection. A year later, deteriorating
handwriting lead to the diagnosis of three presumed
metastases in the right cerebellum. She underwent frac-
tionated whole brain radiation therapy to 30 Gy with a
focal boost to 39 Gy. Nine months later, two of the three
lesions were found to be enlarging and she was referred
for radiosurgery. All three lesions were treated with two
isocenters, delivering 15 Gy to the 82% isodose line of
a 3.6 cc target and 15 Gy to the 82% isodose line of
a 0.19 cc target. Fifteen months later, the lesions were
still present, but had not enlarged since treatment. She
died of systemic disease 17 months after radiosurgery.
Target lesion larger
M.N., a 52-year-old woman, was diagnosed with breast
cancer 4 years earlier and had undergone lumpectomy,
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radiation, and chemotherapy. Three years later, she
developed a left frontal metastasis which was resected
elsewhere. She then underwent fractionated whole
brain radiation to 30 Gy with a 10 Gy boost to the
resection site. One year later, two asymptomatic right
parietal and occipital tumors were detected and she
was referred for radiosurgery. She received 18 Gy to
the 87% isodose line of a 6.48 cc target and 18 Gy
to the 81% isodose line of a 3.99 cc target. An MRI
2 months later showed both lesions to be larger, and was
interpreted by the radiologist as showing progression.
A thallium 201 SPECT scan was obtained by the
referring oncologist 4 months after radiosurgery and
was interpreted as showing significant uptake in
both of the tumors. The patient was treated with
steroids, but became progressively debilitated and
expired 6 months after radiosurgery. No autopsy was
performed.
R.L., a 56-year-old man, had undergone a nephrec-
tomy for renal cell carcinoma 2 years earlier. Because
of pulmonary metastases, he was under consideration
for immunotherapy. A screening head CT disclosed a
left frontal polar asymptomatic presumed metastasis
and he was referred for radiosurgery. He received 21 Gy
to the 83% isodose surface of a 1.0 cc target. After
some consideration, he then underwent fractionated
whole brain radiotherapy to a total dose of 37.5 Gy
delivered in 2.5 Gy fractions. Five months later, he was
referred emergently to neurosurgery for consideration
of resection because a follow up MRI showed a massive
increase in the enhancing abnormality. An FDG-PET
scan was obtained which was read as showing
Figure 2. Metastatic renal cell carcinoma. Axial contrast enhanced CT scan from day of radiosurgery (left), and axial, T1 weighted,
gadolinium enhanced MRI from 8 months (center) and 11 months (right) after radiosurgery. The patient received 21 Gy to the 83% isodose
surface of a 1.0 cc tumor. The radiographic abnormality has increased in size, but shows ring enhancement only.
increased uptake consistent with recurrent/persistent
tumor. It was the opinion of the radiosurgery team that
this was not likely to be the case, and no further therapy
was recommended other than steroids for symptomatic
relief. Another MRI 2 months later, showed a marked
decrease in the enhancement. The patient remains
asymptomatic 20 months after treatment (Figure 2).
M.R., a 21-year-old woman, experienced her first
seizure. MRI showed a large right frontal intra-
axial mass without contrast enhancement. The lesion
was entirely resected at an awake craniotomy, with
complete resection confirmed by a post-operative MRI.
Pathology was a Grade III ganglioglioma. She received
fractionated radiation therapy to 45 Gy with a boost to
75.6 Gy. Six weeks later, MRI showed a new contrast
enhancing nodule in the wall of the resection cavity and
radiosurgery was recommended. She received 17 Gy to
the 84% isodose surface of a 5.7 cc target. One month
later, the mass had increased in size on CT and the
patient had developed a hemiparesis. An FDG-PET
scan was obtained and showed a focal area of increased
uptake corresponding to the contrast enhancing region
and interpreted as tumor progression. PCV chemother-
apy was begun. Five months after radiosurgery the scan
continued to worsen, so chemotherapy was changed to
carboplatin and VP-16. One year after radiosurgery, the
enhancement had diminished markedly. Twenty-three
months later, there is no contrast enhancement on her
MRI scan (Figure 3).
G.J., a 51-year-old man, was diagnosed with a
left frontal Grade III oligoastrocytoma 8 years pre-
viously. After radical resection, he received 59.4 Gy
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Figure 3. Recurrent high grade ganglioglioma after fractionated radiation. Axial, contrast enhanced CT on the day of treatment (left),
and axial, T1 weighted, gadolinium enhanced MRI from 5 months (center) and 23 months (right) after radiosurgery. The patient received
17 Gy to the 84% isodose surface of a 5.7 cc mass.
of fractionated radiation. Serial imaging showed no
residual tumor until 5 years after surgery, at which time
a new area of contrast enhancement was detected and
radiosurgery was recommended. He received 18 Gy
to the 80% isodose surface of the 4.9 cc target. For
the next 15 months, the radiographic lesion enlarged
steadily, but the patient was asymptomatic. No addi-
tional therapy was recommended. The lesion then
began to decrease in size. Three years after treatment,
the lesion was no longer visible on CT.
Discussion
Although radiosurgical treatment of malignant primary
and secondary brain tumors has become quite common,
very little has been written about the interpretation of
post-treatment imaging studies. Many comprehensive
reports do not mention interpretation of post-treatment
imaging except in relation to radiation necrosis [7,11].
Some reports consider radiographic enlargement an
indication of treatment failure [16].
In a multi-institutional report of outcome of
122 patients after radiosurgery for single brain metas-
tasis, results were reported at a median follow up of
123 weeks as 25% complete response, 34% partial
response, 36% no response, and 6% progression [2].
No mention is made in this report of enlargement of
the target lesion not thought to be due to tumor pro-
gression. The 6% rate of target enlargement is quite
different from our experience, but is reported at much
longer mean follow up, after much of the transient
enlargement secondary to treatment effect would have
resolved. Engenhart et al. [21] reported on 102 treated
metastases in 69 patients, noting complete response in
20%, partial response in 35%, stable disease in 40%,
and progression in 5%. One patient underwent cran-
iotomy for what proved to be radiation necrosis, but no
mention is made of how progression was determined.
Increased perilesional edema and clinical worsening
was noted in 10%. The University of Pittsburgh group
reported that 10.8% of 229 metastases were seen to
grow on subsequent imaging [3]. This report acknowl-
edges that some of the patients classified as recurrences
may have had radiation necrosis, but no patient had his-
tologic confirmation. A later report from the same insti-
tution noted that 5 of 78 metastases (6.5%) were seen
to enlarge on subsequent imaging [22]. Loeffler et al.
[5] noted that metastatic adenocarcinomas decreased
in size rapidly after treatment, but did not often regress
completely. Other tumor types regressed very little
after treatment and, at one year post-treatment, most
patients had smaller ring-enhancing lesions with some
persisting perilesional edema. They noted that it was
important not to overreact to the presence of a persist-
ing radiographic abnormality. Mehta et al. [6] reported
that of 10 metastatic tumors which progressed after
radiosurgery, three occurred after no initial response
to treatment and three occurred after partial responses.
Adler et al. [23] also noted that in 9% of their cases,
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Table 1. Fraction of metastatic tumors enlarging on subsequent
imaging
Reference Patients/tumors Progression (%)
Flickinger et al. [3] 157/229 10.8
Auchter et al. [2] 122/122 6
Engenhart et al. [21] 69/102 5
Mehta et al. [10] 40/58 18.5
Ross 35/37 22
after an initial decrease in the size of the enhancing
abnormality, the lesion then enlarged. Biopsy of two
such lesions showed only necrosis. They concluded
that ‘an assessment of local treatment failure, which is
based solely on an increase in contrast enhancement
observed on imaging studies, is difficult.’ Results are
summarized in Table 1.
In our experience, this has been even more chal-
lenging with malignant gliomas. Mehta et al. [10]
reported on 31 patients with glioblastomas undergoing
radiosurgery as part of initial therapy. Progression was
classified as within the high dose radiosurgical region,
within 2 cm of the border of the high dose region,
or greater than 2 cm from the tumor margin. They
noted ‘the delineation of progression, recurrence, and
necrosis in glioblastoma is not possible to make with
absolute clarity in each case.’ Eighty-four percent of
the patients progressed on clinical grounds, and 83% of
24 evaluable patients were thought to have progressed
based on serial imaging, including MRI, MRS, PET,
and SPECT. Of these 24 patients, no failures were
within the high dose region, 19 were peripheral fail-
ures, four were distant, and one was both peripheral
and distant. Four of these 31 patients were ultimately
determined to have necrosis based upon PET and/or
SPECT in one patient and biopsies in two, for a false
positive rate of 13%. All three of these were thought
to have progressed radiographically, indicating ‘the
potential pitfalls in relying on a radiographic diagnosis
of progression.’ Shrieve et al. [11] noted that among
14 patients undergoing reoperation after radiosurgery
for recurrent glioblastoma, pathological examination
showed both necrosis and tumor cells in all cases,
and that there was no correlation between the find-
ings at surgery and the eventual outcome. Likewise,
the Pittsburgh group reported that 12% of glioblastoma
patients and 23% of anaplastic astrocytoma patients
required reoperation after radiosurgery, with the indi-
cation for surgery described as an increase in tumor
volume and regional mass effect [9]. The pathology
reports on these patients showed a mixture of viable
tumor and necrosis in almost all cases, but these
authors noted ‘it is difficult to know the significance
of each histologic finding on the clinical and imaging
progression observed.’
Additional radiologic studies, such as FDG-PET and
thallium 201 and/or HMPAO SPECT [12–14], have
been reported to be of use in discriminating between
tumor progression and radiation effect. Thompson
et al. [24] studied 15 patients with surgical histo-
logical confirmation of diagnosis and reported that
FDG-PET was only 43% sensitive in distinguishing
recurrent tumor from radiation effect, and was least
accurate when the lesion volume was under 6 cc.
Schwartz et al. [14] have reported that the combina-
tion of low thallium and low HMPAO uptake is associ-
ated with benign radiation changes at surgery; whereas,
increased uptake of either agent or both was associ-
ated with recurrent/persistent tumor at biopsy and a
poor prognosis. However, false positive FDG-PET and
Tl-210 SPECT have been reported with biopsy proven
radiation necrosis [25]. Our own experience underlines
the need for care in interpreting these studies as well.
In particular, FDG-PET was falsely positive in six of
eight cases and falsely negative in two of three cases,
and may not be useful in this setting for predicting
progression of the tumor. Increased FDG uptake might
indicate that more closely spaced surveillance imaging
or biopsy is necessary, but we do not recommend that
it be used as the sole indicator for additional treatment.
Thallium SPECT was more reliable in our institution,
but not universally so. MR spectroscopy may prove
useful in this setting [26].
The pattern of contrast enhancement may be useful
in the case of metastatic tumors. Whereas the tumors
themselves tend to have discrete borders with adjacent
brain on enhanced MRI, radiation effect is more likely
to produce a fuzzy, indiscrete pattern of enhancement
suggestive of breakdown of the blood–brain barrier
adjacent to the target (see Figure 3).
In conclusion, radiographic worsening after radio-
surgery for malignant primary and secondary brain
tumors is quite common. Neurosurgeons, radiation
oncologists, and neuro-oncologists caring for patients
undergoing radiosurgery should be aware of this
phenomenon and be cautious in interpreting post-
treatment images. FDG-PET and Tl-201 or HMPAO
SPECT may be helpful, but are not always reli-
able in discriminating necrosis from recurrent tumor.
Further evaluation of the combination of Tl-201 and
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